A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma
Study of Drug in Patients with Sarcoma
Sponsor: Alliance
Enrolling: Male and Female Patients
IRB Number: AAAQ5401
U.S. Govt. ID: NCT02601209
Contact: Gary Schwartz, MD: 212-305-2055 / gks2123@cumc.columbia.edu
Additional Study Information: This partially randomized phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Have you been diagnosed with bone or soft tissue sarcoma? Yes No
Have you had at least one prior chemotherapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Gary Schwartz, MD